Physician profile
Roberto Corvo-Bequer
NPI 1427582642
$5,306.20
in general payments reported to CMS, 2019-2025
23 companies · $958 in 2025
The $958 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $387 · 2021: $685 · 2022: $1,328 · 2023: $1,034 · 2024: $913 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,892 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,891.91 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,092.26 | 2021-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,035.89 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $729.50 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $595.72 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $338.02 | 2020-2021 | |
| Abbott Laboratories | $285.87 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Sanofi-Aventis U.S. LLC | $252.72 | 2020-2023 | |
| Corcept Therapeutics | $238.55 | 2024-2025 | Korlym |
| Pfizer INC. | $218.85 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $135.71 | 2021-2025 | Jardiance, Stiolto Respimat |
| Amgen INC. | $116.99 | 2024-2025 | Repatha, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $54.87 | 2022-2025 | |
| Glaxosmithkline, LLC. | $31.10 | 2021-2023 | Shingrix, Trelegy Ellipta |
| Nevro Corp. | $24.12 | 2023 | Senza |
| Phathom Pharmaceuticals, INC. | $23.78 | 2025 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.06 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $19.17 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.66 | 2023 | Xarelto |
| Novartis Pharmaceuticals Corporation | $16.74 | 2022 | |
| Merck Sharp & Dohme LLC | $15.56 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Tolmar, INC. | $15.44 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $13.52 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.10 | 2024 | Xifaxan, Trulance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roberto Corvo-Bequer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.